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Oxidative stress-induced endothelial dysfunction plays a key role in ischemia/reperfusion injury. Recent evidence indicates that
endothelial progenitor cell-derived microvesicles (EPC-MVs) can promote angiogenesis of endothelial cells (ECs). Here, we
investigated the potential effects of EPC-MVs on hypoxia/reoxygenation (H/R) injury in human brain microvascular ECs (hbECs). MVs were prepared from EPCs cultured in a serum deprivation (SD) medium (starving stress, sEPC-MVs) or SD medium
containing tumor necrosis factor-𝛼 (TNF𝛼) (apoptotic stress, aEPC-MVs). H/R injury model of hb-ECs was produced by 6 hr
hypoxia (1% O2 ) and 24 hr reoxygenation. The H/R hb-ECs were co-cultured with EPC-MVs. Results showed that (1) H/R hbECs were dysfunctional and coupled with increased apoptosis and ROS overproduction; (2) under two different conditions, EPCs
displayed remarkable difference in caspase 3 and miR126 expression, which were carried by the corresponsive EPC-MVs; (3)
functionally, sEPC-MVs had beneficial effects on H/R hb-ECs, whereas aEPC-MVs had detrimental effects; (4) the diverse effects of
sEPC-MVs and aEPC-MVs were associated with the changes in miR126 and eNOS expression and were abolished by PI3K inhibitor.
In conclusion, sEPCs-MVs and aEPC-MVs are functionally different on hb-EC apoptosis and dysfunction via their carried RNAs
associated with ROS production and PI3K/eNOS/NO pathway.

1. Introduction
Reactive oxygen species (ROS) are well known to mediate
ischemia/reperfusion (I/R) injury [1]. ROS-induced vascular
endothelial cell (EC) injury is the first key step in the pathogenesis of ischemia/reperfusion injury. Therefore, attenuating
oxidative stress-induced EC injury could be an important
strategy in the management of I/R injury on tissues. Several
strategies for inhibiting ROS production or increasing their
degradation and scavenging have been attempted and turned
out to be less effective [2]. Therefore, novel approaches are
greatly demanded for preventing I/R injury.

Endothelial progenitor cells (EPCs) are circulating bone
marrow-derived precursors which are able to exert a protective effect in experimental models of hindlimb ischemia [3]
and myocardial infarction [4]. Previous studies have shown
that EPCs recruited into the kidney could induce tissue repair
via secretion of proangiogenic factors [5, 6].
Microvesicles (MVs) are small particles 0.1–1 𝜇m in size,
which are shed from the plasma membrane of various cell
types [7, 8]. They carry proteins and gene messages (mRNAs
and miRNAs). Because of their ability to merge with target
cells, MVs can deliver their contents into the cells they communicate with [8–10]. Recent studies have reported that MVs
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produced from mesenchymal stem cells and EPCs could exert
protective effects in experimental models of acute/chronic
kidney injury [11–13]. In addition, another study demonstrates that MVs released from EPCs (EPC-MVs) can trigger
angiogenesis by a horizontal transfer of mRNA [14]. Nevertheless, there is little information regarding the effects of
EPC-MVs on ECs injured by hypoxia/reoxygenation (H/R).
In this study, we aimed to investigate the potential effects
of EPC-MVs on human brain microvascular ECs (hb-ECs)
injured by H/R and the underlying mechanisms.

2. Material and Methods
2.1. Culture and Characterization of EPCs. The mononuclear
cells (MNCs) isolated from mouse bone marrow were used
for EPC culture as previously described [15, 16]. In brief,
the cells were counted and plated (1 × 106 cells/well) on
fibronectin-coated 24-well plates (BD Bioscience, San Jose,
CA) and then grown in endothelial cell basal medium2 (EBM-2) supplemented with 5% FBS containing EPC
growth cytokine cocktail (Lonza, Walkersville, MD). After
3 days, nonadherent cells were removed by washing with
PBS. Thereafter, culture medium was changed every 2 days.
Cultured cells were characterized by double-positive Di-LDL
and Bs-Lectin staining as previously reported [15, 16].
2.2. Preparation of EPC-MVs. EPC-MVs were prepared from
EPCs using two different stimulations, starving stress and
apoptotic stress, based on previous reports with slight modifications [13, 17]. EPCs were cultured in serum deprivation
(SD) medium for 24 hrs for generating starving stress EPCMVs (sEPC-MVs). For generating apoptotic stress EPCMVs (aEPC-MVs), EPCs were cultured in SD medium supplemented with 25 ng/mL TNF𝛼 (R&D systems, MN) for
24 hrs. MVs collected from EPCs cultured in EBM-2 served
as a control (control MVs).
2.3. Characterization and Labeling of EPC-MVs. EPC-MVs
were collected from EPC modified culture medium as previously described with slight modification [13]. In brief, EPC
culture medium was collected, centrifuged at 2000 g for
20 mins to remove cells and debris, and ultracentrifuged at
120,000 g for 1 hr. The protein concentration of EPC-MV
preparations was quantified by the Bradford method (BioRad, Hercules, USA). A concentration of 10 𝜇g/mL EPC-MVs
was used for coculture experiments. In selected experiments,
EPC-MVs were pretreated with 0.1% Triton-100 for 5 mins,
then treated with 200 u/mL RNase (Qiagen, CA) for 90 mins
at 37∘ C, washed, and pelleted by ultracentrifugation. To
verify the effect of RNase, the total RNAs of EPC-MVs were
extracted using the RNA isolation kit (Ambion, NY), and the
RNA concentration was determined using quantitative assay
(Thermo Scientific, Nanodrop 2000c, FL). For flow cytometry
analysis [18], EPC-MVs were resuspended and incubated for
30 mins at 4∘ C in the dark with Alexa-488-labeled Annexin
V, PE-conjugated VEGFR2, or FITC-conjugated CD34, 5 𝜇L,
respectively. Isotype matched (IgG) nonspecific antibodies
served as negative controls. All antibodies were purchased
from eBioscience (San Diego, CA). After incubation, labeled
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cells were resuspended with PBS and analyzed under flow
cytometry (Accuri C6 flow cytometer, Ann Arbor, MI). For
TEM analysis [18], EPC-MVs were fixed with 2% glutaraldehyde and postfixed with 1% osmium (all were purchased from
electron microscopy science, Hatfield, PA), then embedded
with Spurr resin (Sigma, Louis, MO), and baked at 60∘ C
according to the manufacturer’s instruction. Ultrathin sections (60–80 nm) were prepared with MT7000, mounted on
300-mesh copper grids, and stained with uranyl acetate and
lead citrate. All samples were examined with an EM 208
(Philips) transmission electron microscope at an accelerating
voltage of 70 KV.
EPC-MVs were labeled with PKH26 (Sigma Aldrich, St.
Louis, MO) according to the manufacturer’s protocol with
some modifications [19]. In brief, EPC-MVs were labeled
with 2 𝜇M PKH26 dye in PBS for 5 mins at room temperature
(RT). An equal volume of FBS was added to stop staining.
EPC-MVs were then ultracentrifuged and resuspended with
culture medium for coculture experiments.
2.4. H/R Injury Model in Hb-ECs. Hb-ECs were purchased
from Cell Systems (Kirkland, WA) and cultured according
to the manufacturer’s protocol. Briefly, cells were cultured in
CSC complete medium containing 10% serum, 2% human
recombinant growth factors, and 0.2% antibiotic solution
under standard cell culture conditions (5% CO2 , 37∘ C). All
medium and supplement reagents were purchased from Cell
Systems. Medium was changed twice a week. Passages 4 to
13 of hb-ECs were used for experiments in this study. For
producing an H/R injury model on hb-ECs, hb-ECs were
cultured as previously described with slight modifications
[20]. Briefly, the hb-ECs were changed with fresh culture
medium and cultured for 6 hrs in a hypoxic chamber (1% O2 ,
5% CO2 , and 94% N2 ; Biospherix hypoxia chamber, NY); cells
were then reoxygenated by incubation in a standard 5% CO2
incubator for 24 hrs. Some cells were harvested for apoptotic
assay, western blot, or quantitative real-time PCR (qRT-PCR)
analysis. Some plates of cells were pretreated with or without
LY294002 (PI3K inhibitor) and then cocultured with sEPCMVs, aEPC-MVs, RNase treated sEPC-MVs (RNase-sEPCMVs), or RNase treated aEPC-MVs (RNase-aEPC-MVs). All
experiments were repeated four times. At least six plates per
experiment were used in each group.
2.5. Coculture Assay of EPC-MVs and Hb-ECs. For coculture
experiment between hb-ECs and EPC-MVs [21], the labeled
EPC-MVs were resuspended with CSC medium, then added
to hb-ECs, and cultured for 2 hrs in an incubator (37∘ C, 5%
CO2 ). Cell nuclei were stained with DAPI. The interaction
between EPC-MVs and hb-ECs was examined under fluorescence microscope.
2.6. Gene Expression Analysis. MicroRNA 126 (miR126)
from EPCs, EPC-MVs, and H/R hb-ECs was extracted by
using mirVana miRNA isolation kit (Ambion) following
manufacturer’s instructions. cDNA was synthesized using
miScript reverse transcription kit (QIAGEN). Quantitative real-time PCR was conducted with miR126 specific
primers and miScript SYBR Green PCR Kit (QIAGEN) on
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a real-time PCR system (Bio-Rad). Small nuclear RNA U6
(U6) was used as an internal control. Relative expression of
miR126 was calculated using the 2−ΔΔCT method [22].
2.7. Cell Viability Analysis. The cell viability of H/R hbECs was examined using methyl thiazolyl tetrazolium (MTT,
Invitrogen, NY) method [23]. In brief, cells cultured in 96well plate were incubated with 10 𝜇L MTT solution (12 mM)
for 4 hrs at 37∘ C, then 100 𝜇L sodium dodecyl sulfate (SDS)HCl solution was added to each well, and the cells were
incubated for another 4 hrs at 37∘ C. The absorbance of cells
was read at 535 nm. The percent of cell viability was defined as
the relative absorbance of treated cells versus untreated cells.
2.8. Apoptosis Assay. The apoptosis assay of EPCs and H/R
hb-ECs was conducted using FITC Annexin V apoptosis
detection kit (BD Biosciences, CA) as previously described
[23]. Briefly, cells were washed with PBS, resuspended with
100 𝜇L 1x annexin-binding buffer, incubated with 5 𝜇L FITCconjugated Annexin V and 5 𝜇L propidium iodide (PI) for
15 mins in the dark, and then analyzed by flow cytometry. The
apoptotic cells were defined as Annexin V+/PI− cells. The
experiment was repeated four times. At least six plates per
experiment were used in each group.
2.9. Tube Formation Assay. The tube formation ability of
EPCs and hb-ECs cocultured with EPC-MVs was evaluated
using tube formation assay kit (Chemicon) as we previously
described [24]. Briefly, ECMatrix solution was thawed on
ice overnight, mixed with 10x ECMatrix diluent buffer, and
placed in a 96-well tissue culture plate at 37∘ C for 1 hr to
allow the matrix solution to solidify. Then the cells were replated (1 × 104 cells/well) onto the surface of the solidified
ECMatrix and incubated for 24 hrs at 37∘ C. Tube formation
was evaluated with an inverted light microscope and defined
as a tube structure exhibiting a length 4 times its width.
Five independent fields were assessed for each well, and the
average number of tubes per field (magnification, 200x) was
determined.
2.10. Measurement of ROS. Intracellular ROS production
was determined by dihydroethidium (DHE) (Sigma) staining
followed by flow cytometric analysis. Briefly, cells were incubated with 2 𝜇M DHE solution at 37∘ C for 2 hrs, washed with
PBS twice, trypsinized, and centrifuged. The fluorescence
intensity of cells was analyzed by flow cytometry.
2.11. Measurement of NO. The membrane-permeable indicator diaminofluorescein (DAF-FM) diacetate (Invitrogen,
Grand Island, NY) was used to assess NO production [16].
Briefly, the hb-ECs were incubated with 2 𝜇M DAF-FM
diacetate in serum-free CSC medium at 37∘ C for 30 mins,
washed with PBS twice, then incubated with CSC medium for
20 mins to allow complete de-esterification of the intracellular diacetates. DAF-FM fluorescence was measured using a
spectrofluorometer.
2.12. Western Blot Analysis. Proteins from H/R hb-ECs
were extracted with lysis buffer. Protein lysates were
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electrophoresed through SDS-PAGE gel and transferred
onto PVDF membranes. The membranes were blocked
for 1 hr and incubated with primary antibodies against
eNOS (Cell Signaling Technology) and 𝛽-actin (Sigma)
at 4∘ C overnight. After washing 3 times, membranes were
incubated with horseradish-peroxidase- (HRP-) conjugated
IgG (Jackson ImmunoResearch Lab) for 1 hr at RT. Blots
were then developed with enhanced chemiluminescence
developing solutions and quantified under ImageJ software.
2.13. Enzyme-Linked Immunosorbent Assay. The levels of
caspase 3 in EPCs, EPC-MVs, and H/R hb-ECs were
measured by enzyme-linked immunosorbent assay (ELISA)
[25]. Briefly, cells or EPC-MVs were washed in PBS and
their extracts were prepared according to the manufacturer’s
instructions before being analyzed by ELISA (R&D System,
Quantikine).
2.14. Statistical Analysis. All data was expressed as mean ±
SEM. Comparison for two groups was examined by Student’s
𝑡-test. Multiple comparisons were performed by one- or twoway ANOVA. SPSS software version 17.0 was used. For all
tests, a value of 𝑃 < 0.05 was considered statistically significant.

3. Results
3.1. The sEPC-MVs and aEPC-MVs Carried the Characters
of Their Parent EPCs. As we previously reported [16], EPCs
were defined as the cells uptaking Di-LDL and binding with
Bs-Lectin (Figure 1(a)). As expected, EPCs in an apoptotic
stress condition (SD plus TNF𝛼 stimulation) had a significantly higher apoptotic rate than that of EPCs in a starving
stress (SD only) or normal culture condition (versus control
or SD; 𝑃 < 0.05; 𝑛 = 4/group; Figure 1(b)). Moreover, gene
expression of caspase 3 was upregulated, whereas miR126 was
down-regulated in EPCs in the SD+TNF𝛼 group as compared
to control group. In SD group, both caspase 3 and miR126
expressions were higher than those in control (versus control;
𝑃 < 0.05; 𝑛 = 4/group; Figures 1(c)-1(d)).
According to the flow cytometric analysis, both aEPCMVs and sEPC-MVs positively expressed Annexin V and
EPC specific markers (CD34, VEGFR2) (Figure 2(a)). The
TEM results showed that there was no difference in morphology between sEPC-MVs and aEPC-MVs (Figure 2(b)). With
the digestion of RNase, the total RNAs of both EPC-MVs
were significantly decreased (Figure 2(c)). More interestingly,
the gene expressions of caspase 3 and miR126 were displayed
in the same pattern as that in their parent EPCs. The results
showed that caspase 3 was upregulated in aEPC-MVs as
compared to that in sEPC-MVs or control, and miR126 was
down-regulated in aEPC-MVs as compared to that in sEPCMVs or control (versus control or sEPC-MVs; 𝑃 < 0.05;
𝑛 = 4/group; Figure 2(d)).
3.2. The Model of H/R Injury in Hb-ECs Was Confirmed
by ROS Overproduction, Cell Dysfunction, and Apoptosis.
Hb-ECs were exposed to hypoxia (6 hrs) and followed by
reoxygenation (24 hrs). As shown in Figure 3(a), MTT assay
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Figure 1: Effects of serum deprivation (SD) alone and SD plus TNF𝛼 on EPC apoptosis, caspase 3, and miR126 expression. (a) Representative
images showing EPC characterization of Bs-Lectin and Di-LDL double staining. Scale bar: 100 𝜇m. (b) Apoptosis (Annexin V+PI−) of
stimulated EPCs. (c) Caspase 3 expression in stimulated EPCs. (d) MiR126 expression in stimulated EPCs. ∗ 𝑃 < 0.05, versus control; # 𝑃 < 0.05,
versus SD; 𝑁 = 4/group.

showed that H/R decreased hb-EC viability (versus control;
𝑃 < 0.05; 𝑛 = 4/group). To confirm this observation, we
also performed apoptotic assay and found that H/R hb-ECs
had a higher apoptotic rate than those cultured in normoxia
condition (versus control; 𝑃 < 0.05; 𝑛 = 4/group; Figure
3(a)). In addition, in H/R hb-ECs, the ROS production was
increased, whereas, the NO production was decreased. And
tube formation ability of H/R hb-ECs was decreased (versus
control; 𝑃 < 0.05; 𝑛 = 4/group; Figures 3(b)-3(c)). These
findings indicated the success of H/R injured model on
hb-ECs.
3.3. sEPC-MVs Decreased Whereas aEPC-MVs Increased ROS
Production and Apoptosis in H/R Hb-ECs via PI3K Pathway. After coculture the hb-ECs with EPC-MVs for 24 hrs,
the PKH26 fluorescence was observed in the cytoplasm of

hb-ECs, suggesting the EPC-MVs were incorporated into the
hb-ECs (Figure 4(a)). Interestingly, the miR126 expression
was upregulated in the hb-ECs cocultured with sEPC-MVs
and down-regulated in the hb-ECs cocultured with aEPCMVs as compared to vehicle (versus vehicle; 𝑃 < 0.05,
𝑛 = 4/group; Figure 4(b)). According to flow cytometric analysis (Figures 4(c)-4(d)), sEPC-MVs decreased the
apoptosis level and ROS production in H/R hb-ECs (versus
vehicle; 𝑃 < 0.05, 𝑛 = 4/group). On the contrary, aEPCMVs increased the apoptosis level and ROS production in
H/R hb-ECs (versus vehicle; 𝑃 < 0.05, 𝑛 = 4/group). As
expected, RNase-sEPC-MVs were less effective on decreasing
the level of apoptosis and ROS production in H/R hb-ECs. In
addition, preincubation of H/R hb-ECs with PI3K inhibitor
(LY294002) abolished the aforementioned effects of sEPCMVs and aEPC-MVs (𝑃 < 0.05, 𝑛 = 4/group).
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Figure 2: EPC-MV characterization, modification, caspase 3 and miR126 expression. (a) Flow cytometric plots showing Annexin V, CD34
and VEGFR2 expressions (isotype controls: left curves; antibodies: right curves) in EPC-MVs. (b) TEM image showing similar spherical
morphology of sEPC-MVs and aEPC-MVs. Scale bar: 500 nm. (c) Summarized data showing effective digestion of EPC-MVs total RNAs
by RNase treatment. (d) Caspase 3 and miR126 expression in control MVs (generated from basal condition), sEPC-MVs, and aEPC-MVs.
∗
𝑃 < 0.05, versus control; # 𝑃 < 0.05, versus sEPC-MVs; & 𝑃 < 0.05, versus aEPC-MVs; 𝑁 = 4/group. TEM and transmission electron
microscopy.

3.4. sEPC-MVs Increased Whereas aEPC-MVs Decreased
eNOS and NO Production in H/R Hb-ECs via PI3K Pathway. As shown in Figures 5(a)-5(b), sEPC-MVs significantly
upregulated eNOS and NO expressions in the H/R hb-ECs
(versus vehicle, 𝑃 < 0.05, 𝑛 = 4/group). On contrary,
aEPC-MVs decreased the eNOS and NO production in H/R
hb-ECs (versus vehicle; 𝑃 < 0.05, 𝑛 = 4/group). Again,
RNase-sEPC-MVs were less effective on increasing whereas
RNase-aEPC-MVs were less effective on decreasing the eNOS
and NO production in H/R hb-ECs. Similarly, preincubation
of H/R hb-ECs with LY294002 attenuated these effects (𝑃 <
0.05, 𝑛 = 4/group).

3.5. sEPC-MVs Increased Whereas aEPC-MVs Decreased the
Hb-EC Tube Formation Ability in H/R Hb-ECs via PI3K
Pathway. As shown in Figure 5(c), the tube formation ability
of H/R hb-ECs was increased after coculture with sEPCMVs, whereas it was decreased after coculture with the aEPCMVs (𝑃 < 0.05, 𝑛 = 4/group). Again, preincubation with
LY294002 abolished this effect.

4. Discussion
There are three major findings in this study. Firstly, we
demonstrated that EPCs stressed with SD (sEPCs) or SD plus
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Figure 5: Effects of EPC-MVs on eNOS expression, NO production, and tube formation in H/R hb-ECs. (a) eNOS production of H/R hb-ECs
cocultured with aEPC-MVs or sEPC-MVs. (b) NO production of H/R hb-ECs cocultured with aEPC-MVs or sEPC-MVs. (c) Tube formation
ability of H/R hb-ECs cocultured with aEPC-MVs or sEPC-MVs. ∗ 𝑃 < 0.05, versus vehicle; + 𝑃 < 0.05, versus sEPC-MVs or aEPC-MVs;
#
𝑃 < 0.05, versus sEPC-MVs or RNase-sEPC-MVs; 𝑁 = 4/group.

TNF𝛼 (aEPCs) have different changes regarding cell apoptotic rate and the expression levels of caspase 3 and miR126.
Secondly, we identified that the MVs released from sEPCs and
aEPCs carry the same characters as their parent cells. Thirdly,
we confirmed that EPC-MVs can merge with hb-ECs and
sEPC-MVs and aEPC-MVs have different functional roles in
H/R-induced hb-ECs injury, which might be dependent on
their effects on ROS and NO generation, miR126 expression,
and regulation of the PI3K/eNOS/NO pathway.
ROS is well known to be implicated in I/R injury [1].
ROS-induced vascular endothelium injury is a pivotal step
in the pathogenesis of I/R injury. Although strategies for
inhibiting ROS production or increasing their degradation
and scavenging have been attempted, they have turned out to
be less effective on the prevention or treatment of I/R injury
[2]. Therefore, novel approaches are intensely needed for preventing I/R injury.
MVs are cellular fragments, which have been shown to
act as a paracrine mediator as they can merge with target cells
for exerting their functions [14]. Several studies have demonstrated that MVs released from mesenchymal stem cells can
protect the kidney from I/R injury [11–13]. In this study, we
generated MVs from EPCs which underwent SD alone or
SD plus TNF𝛼 stimulation and examined the effects of both
stimuli on EPCs and their released MVs. We found that both
apoptosis and caspase 3 expression of EPCs were significantly
increased in the SD plus TNF𝛼 stimulation group and slightly
increased in the SD group. Even more interesting, the miR126,
a proangiogenic factor, was upregulated in EPCs stressed
by SD and was downregulated in EPCs stressed by SD plus

TNF𝛼. These data indicate that EPCs underwent different
changes in response to different stimuli.
Next, we examined the morphological and functional
characteristics of sEPC-MVs and aEPC-MVs. We found that
there was no significant difference in morphology and the
expression of parent specific markers between sEPC-MVs
and aEPC-MVs as determined by TEM and flow cytometry.
But there were differences of caspase 3 and miR126 expression
between them. According to the ELISA analysis results, the
caspase 3 expression in aEPC-MVs was higher than that in
sEPC-MVs. The miR126 expression was lower in aEPC-MVs
in comparison to sEPC-MVs as revealed by qRT-PCR assay.
These data indicate that both aEPC-MVs and sEPC-MVs
carry their parent proteins and genetic materials.
Additionally, our data showed that EPC-MVs can be
incorporated by hb-ECs, which suggests that EPC-MVs may
have a functional role in hb-ECs. In order to further test the
potential effects of EPC-MVs, we constructed an H/R hb-EC
injury model, which was characterized by overproduction of
ROS, an increase in apoptosis, and decrease in NO production, cell viability, and tube formation ability. In coculture
experiments, we found that sEPC-MVs protected hb-ECs
from H/R-induced ROS overproduction and apoptosis. Both
the eNOS and NO production were increased in the H/R
hb-ECs cocultured with sEPC-MVs. Moreover, sEPC-MVs
rescued the tube formation disability of H/R hb-ECs. In
addition, we also observed that these protective effects of
sEPC-MVs were abrogated by PI3 K inhibitor LY294002.
These data suggest that sEPC-MVs protect H/R hb-ECs from
injury via activating PI3K/eNOS/NO pathway. Contrary
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to sEPC-MVs, aEPC-MVs showed deleterious effects on
H/R hb-ECs. Our data showed that aEPC-MVs accelerated
ROS overproduction and apoptosis, coupled with decreased
eNOS expression and NO generation. Meanwhile, the tube
formation ability of H/R hb-ECs was also compromised in
the aEPC-MVs groups. Likewise, these deleterious effects of
aEPC-MVs were also abolished by LY294002. These findings
indicate that aEPC-MVs worsen the oxidative stress in H/R
hb-ECs via PI3K/eNOS/NO pathway.
Of note, we also found that all the aforementioned effects
of EPC-MVs were partially diminished by coculture with
RNase-EPC-MVs. Therefore, it is logical to deduce that EPCMV carried RNAs which participated in the protective or
deleterious effects of EPC-MVs. In the present study, we
found that the expression of miR126 in H/R hb-ECs was
increased in the sEPC-MVs group, whereas it was decreased
in the aEPC-MVs group. On contrary, the caspase 3 expression in H/R hb-ECs was decreased in sEPC-MVs group
and increased in aEPC-MVs group. These data suggest that
miR126 and caspase 3 were delivered to hb-ECs from EPCs
via EPC-MVs, which is in agreement with previous studies
showing MVs can deliver and transfer their contents to target
cells [8–10]. Nevertheless, the detailed mechanisms of their
roles need further investigation.

Oxidative Medicine and Cellular Longevity

[2]

[3]

[4]

[5]

[6]

[7]

[8]

5. Conclusion
Our data demonstrate that sEPCs-MVs and aEPC-MVs are
functionally different on H/R-induced apoptosis and dysfunction. These functional roles might rely on the orchestrated mechanisms associated with MV-carried RNAs in control of ROS production and PI3K/eNOS/NO pathway in the
target cells. These findings indicate that EPC-MVs could be
used as a novel vehicle for treating H/R injury.
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